The Pharmaceutical Sector in Ghana
Main pharmaceutical policy goals in Ghana are access to essential medicines for everybody, quality assurance for all drugs on the market, a functioning and efficient supply chain as well as rational use of medicines by professionals and patients. T...
| Main Authors: | , |
|---|---|
| Format: | Policy Note |
| Language: | English en_US |
| Published: |
World Bank, Washington, DC
2017
|
| Subjects: | |
| Online Access: | http://documents.worldbank.org/curated/en/734211468030342727/The-pharmaceutical-sector-in-Ghana-policy-note http://hdl.handle.net/10986/28117 |
| id |
okr-10986-28117 |
|---|---|
| recordtype |
oai_dc |
| repository_type |
Digital Repository |
| institution_category |
Foreign Institution |
| institution |
Digital Repositories |
| building |
World Bank Open Knowledge Repository |
| collection |
World Bank |
| language |
English en_US |
| topic |
ABUSE ACCESS TO HEALTH CARE ACCOUNTABILITY ADEQUATE TREATMENT ADHERENCE TO TREATMENT ADVERSE EVENTS ADVERTISING AIDS CONTROL AIDS CONTROL PROGRAM AIDS RELIEF ANTIBIOTICS AVAILABILITY OF DRUGS BED NETS BIDDING BRAND BRAND NAME BRAND NAMES BRANDS BUDGETING CAPITAL MARKETS CASE MANAGEMENT CASH FLOW CENTRAL MEDICAL STORES CERTIFICATION CHEMISTS CIF CITIZENS CLINICAL PHARMACOLOGY CLINICAL TRIALS CLINICS COMMODITIES COMPETITIVE BIDDING CORRUPTION COUNTERFEIT DRUGS COUNTRIES OF ORIGIN DEBT FORGIVENESS DECENTRALIZATION DECISION MAKING DEVELOPING COUNTRIES DIAGNOSIS DISEASES DOMESTIC MANUFACTURERS DOMESTIC MARKET DRUG CONSUMPTION DRUG INDUSTRY DRUG PRICES DRUG SELECTION DRUG SUPPLY DRUG THERAPY DRUGS DUMPING ECONOMIC GROWTH EMERGENCY CARE ENTITLEMENT EQUAL ACCESS ESSENTIAL DRUGS ESSENTIAL MEDICINES EXPENDITURE EXPENDITURES FAMILIES FAMILY MEMBERS FRAUD GMP GOOD MANUFACTURING PRACTICES HEALTH CARE HEALTH CENTERS HEALTH FACILITIES HEALTH INSTITUTIONS HEALTH INSURANCE HEALTH OUTCOMES HEALTH PLANS HEALTH POLICY HEALTH RISKS HEALTH SECTOR HEALTH SERVICE HEALTH SERVICE PROVIDERS HEALTH SERVICES HEALTH SYSTEM HEALTH WORKERS HEALTHCARE HERBAL PRODUCTS HOSPITAL HOSPITAL PHARMACIES HOSPITALS INSURANCE COVERAGE INSURANCE SCHEMES INSURERS INTERNATIONAL MARKET INTERNATIONAL ORGANIZATIONS INVENTORY INVENTORY MANAGEMENT IRRATIONAL USE LACK OF COMMUNICATION LAND OWNERSHIP LEGAL FRAMEWORK LIFE SAVING LIMITED RESOURCES LOCAL MANUFACTURERS LOW-INCOME COUNTRIES MALARIA MANAGEMENT SYSTEMS MARKET DISTORTION MARKET RESEARCH MARKET RESEARCH FIRM MARKET SHARE MEDICAL DEVICES MEDICAL SCHOOL MEDICATION MEDICINE MEDICINES MICROBIOLOGY MIDWIVES MINISTRIES OF HEALTH MINISTRY OF HEALTH NATIONAL AIDS NATIONAL DRUG NATIONAL HEALTH POLICY PATIENT PATIENTS PAYMENT TERMS PHARMACEUTICAL PHARMACEUTICAL CONSUMPTION PHARMACEUTICAL EXPENDITURE PHARMACEUTICAL INDUSTRY PHARMACEUTICAL MANUFACTURERS PHARMACEUTICAL POLICY PHARMACEUTICAL REGULATION PHARMACEUTICAL SECTOR PHARMACEUTICAL SUPPLY PHARMACEUTICALS PHARMACISTS PHARMACY PHYSICIANS POLICY DIALOGUE POLICY FRAMEWORK POLICY GOALS POLICY IMPLICATIONS POLICY MAKERS POLITICAL SUPPORT POOLED PROCUREMENT PRESCRIPTIONS PRICE COMPETITION PRICE LEVEL PRICE LEVELS PRIVATE PHARMACIES PROCUREMENT PROGRESS PSYCHOTROPIC DRUGS PUBLIC DEBATE PUBLIC HEALTH PUBLIC PHARMACIES PUBLIC PHARMACY PURCHASING PURCHASING POWER QUALITY ASSURANCE QUALITY CONTROL RATIONAL DRUG USE RATIONAL USE OF DRUGS REGIONAL HOSPITAL REGULATORY AGENCIES RESPECT RETAIL RETAIL PHARMACIES RETAIL PRICE RETAIL PRICES ROLE MODELS RURAL AREAS SALE SALES SCREENING SELFMEDICATION SERVICE DELIVERY SERVICE DELIVERY POINTS SERVICE FACILITIES STANDARD TREATMENT GUIDELINES STOCKS SUPPLIER SUPPLIERS SUPPLY CHAIN SUPPLY CHAIN MANAGEMENT SUPPLY CHAINS SUPPLY MANAGEMENT TECHNICAL ASSISTANCE TENDERING THERAPEUTICS TOTAL SALES TREATMENT PREFERENCES TREATMENTS TURNOVER URBAN AREAS VISITS VITAMINS WAREHOUSE WHOLESALER WHOLESALERS WORKERS WORKING CONDITIONS WORLD HEALTH ORGANIZATION |
| spellingShingle |
ABUSE ACCESS TO HEALTH CARE ACCOUNTABILITY ADEQUATE TREATMENT ADHERENCE TO TREATMENT ADVERSE EVENTS ADVERTISING AIDS CONTROL AIDS CONTROL PROGRAM AIDS RELIEF ANTIBIOTICS AVAILABILITY OF DRUGS BED NETS BIDDING BRAND BRAND NAME BRAND NAMES BRANDS BUDGETING CAPITAL MARKETS CASE MANAGEMENT CASH FLOW CENTRAL MEDICAL STORES CERTIFICATION CHEMISTS CIF CITIZENS CLINICAL PHARMACOLOGY CLINICAL TRIALS CLINICS COMMODITIES COMPETITIVE BIDDING CORRUPTION COUNTERFEIT DRUGS COUNTRIES OF ORIGIN DEBT FORGIVENESS DECENTRALIZATION DECISION MAKING DEVELOPING COUNTRIES DIAGNOSIS DISEASES DOMESTIC MANUFACTURERS DOMESTIC MARKET DRUG CONSUMPTION DRUG INDUSTRY DRUG PRICES DRUG SELECTION DRUG SUPPLY DRUG THERAPY DRUGS DUMPING ECONOMIC GROWTH EMERGENCY CARE ENTITLEMENT EQUAL ACCESS ESSENTIAL DRUGS ESSENTIAL MEDICINES EXPENDITURE EXPENDITURES FAMILIES FAMILY MEMBERS FRAUD GMP GOOD MANUFACTURING PRACTICES HEALTH CARE HEALTH CENTERS HEALTH FACILITIES HEALTH INSTITUTIONS HEALTH INSURANCE HEALTH OUTCOMES HEALTH PLANS HEALTH POLICY HEALTH RISKS HEALTH SECTOR HEALTH SERVICE HEALTH SERVICE PROVIDERS HEALTH SERVICES HEALTH SYSTEM HEALTH WORKERS HEALTHCARE HERBAL PRODUCTS HOSPITAL HOSPITAL PHARMACIES HOSPITALS INSURANCE COVERAGE INSURANCE SCHEMES INSURERS INTERNATIONAL MARKET INTERNATIONAL ORGANIZATIONS INVENTORY INVENTORY MANAGEMENT IRRATIONAL USE LACK OF COMMUNICATION LAND OWNERSHIP LEGAL FRAMEWORK LIFE SAVING LIMITED RESOURCES LOCAL MANUFACTURERS LOW-INCOME COUNTRIES MALARIA MANAGEMENT SYSTEMS MARKET DISTORTION MARKET RESEARCH MARKET RESEARCH FIRM MARKET SHARE MEDICAL DEVICES MEDICAL SCHOOL MEDICATION MEDICINE MEDICINES MICROBIOLOGY MIDWIVES MINISTRIES OF HEALTH MINISTRY OF HEALTH NATIONAL AIDS NATIONAL DRUG NATIONAL HEALTH POLICY PATIENT PATIENTS PAYMENT TERMS PHARMACEUTICAL PHARMACEUTICAL CONSUMPTION PHARMACEUTICAL EXPENDITURE PHARMACEUTICAL INDUSTRY PHARMACEUTICAL MANUFACTURERS PHARMACEUTICAL POLICY PHARMACEUTICAL REGULATION PHARMACEUTICAL SECTOR PHARMACEUTICAL SUPPLY PHARMACEUTICALS PHARMACISTS PHARMACY PHYSICIANS POLICY DIALOGUE POLICY FRAMEWORK POLICY GOALS POLICY IMPLICATIONS POLICY MAKERS POLITICAL SUPPORT POOLED PROCUREMENT PRESCRIPTIONS PRICE COMPETITION PRICE LEVEL PRICE LEVELS PRIVATE PHARMACIES PROCUREMENT PROGRESS PSYCHOTROPIC DRUGS PUBLIC DEBATE PUBLIC HEALTH PUBLIC PHARMACIES PUBLIC PHARMACY PURCHASING PURCHASING POWER QUALITY ASSURANCE QUALITY CONTROL RATIONAL DRUG USE RATIONAL USE OF DRUGS REGIONAL HOSPITAL REGULATORY AGENCIES RESPECT RETAIL RETAIL PHARMACIES RETAIL PRICE RETAIL PRICES ROLE MODELS RURAL AREAS SALE SALES SCREENING SELFMEDICATION SERVICE DELIVERY SERVICE DELIVERY POINTS SERVICE FACILITIES STANDARD TREATMENT GUIDELINES STOCKS SUPPLIER SUPPLIERS SUPPLY CHAIN SUPPLY CHAIN MANAGEMENT SUPPLY CHAINS SUPPLY MANAGEMENT TECHNICAL ASSISTANCE TENDERING THERAPEUTICS TOTAL SALES TREATMENT PREFERENCES TREATMENTS TURNOVER URBAN AREAS VISITS VITAMINS WAREHOUSE WHOLESALER WHOLESALERS WORKERS WORKING CONDITIONS WORLD HEALTH ORGANIZATION Seiter, Andreas Gyansa-Lutterodt, Martha The Pharmaceutical Sector in Ghana |
| geographic_facet |
Africa Ghana |
| description |
Main pharmaceutical policy goals in
Ghana are access to essential medicines for everybody,
quality assurance for all drugs on the market, a functioning
and efficient supply chain as well as rational use of
medicines by professionals and patients. There is also a
commitment to strengthen the domestic pharmaceutical
industry, outlined under health industry in the national
health policy. The National Health Insurance System (NHIS)
has significantly improved access to medicines for insured
patients, measured in increased utilization of facilities
and rapidly growing turnover of revolving drug funds. The
risk is now that non-rational prescribing and fraud lead to
a growing medicine bill that threatens financial
sustainability of NHIS. On the other hand, National Health
Insurance Authority (NHIA) has the resources and purchasing
power to influence provider behavior as well as the market
in terms of quality and price. The purpose of this policy
note is to provide a compact overview of the situation,
trends and opportunities in the pharmaceutical sector in
Ghana as relevant to the strategic objectives in the five
year program of work. It summarizes data from a number of
recent studies and reports that were done by a range of
partners inside and outside the country as well as
discussions with key stakeholders in the sector. The intent
is to give decision makers up-to-date background information
and provide some suggestions for specific policy initiatives
designed to achieve the work program objectives, with a
particular focus on the role health insurance can play to
stabilize and improve service delivery, increase access to
quality medicines and promote rational use. The overall
legal framework for the pharmaceutical sector is set by the
Food and Drugs Law from 1992, amended by Act 523 in 1996. It
defines the role of the food and drugs board as separate
entity under control of the Ministry of Health (MOH),
responsible for regulating the sector. The Food and Drugs
Board (FDB) also runs the official drug quality control
laboratory that is in charge of testing quality samples
obtained from manufacturers, importers, distributors or
other sources. The FDB is also working on an improvement of
its public website in an effort to strengthen communication
with the general public to increase transparency and improve governance. |
| format |
Policy Note |
| author |
Seiter, Andreas Gyansa-Lutterodt, Martha |
| author_facet |
Seiter, Andreas Gyansa-Lutterodt, Martha |
| author_sort |
Seiter, Andreas |
| title |
The Pharmaceutical Sector in Ghana |
| title_short |
The Pharmaceutical Sector in Ghana |
| title_full |
The Pharmaceutical Sector in Ghana |
| title_fullStr |
The Pharmaceutical Sector in Ghana |
| title_full_unstemmed |
The Pharmaceutical Sector in Ghana |
| title_sort |
pharmaceutical sector in ghana |
| publisher |
World Bank, Washington, DC |
| publishDate |
2017 |
| url |
http://documents.worldbank.org/curated/en/734211468030342727/The-pharmaceutical-sector-in-Ghana-policy-note http://hdl.handle.net/10986/28117 |
| _version_ |
1764465769861611520 |
| spelling |
okr-10986-281172021-04-23T14:04:46Z The Pharmaceutical Sector in Ghana Seiter, Andreas Gyansa-Lutterodt, Martha ABUSE ACCESS TO HEALTH CARE ACCOUNTABILITY ADEQUATE TREATMENT ADHERENCE TO TREATMENT ADVERSE EVENTS ADVERTISING AIDS CONTROL AIDS CONTROL PROGRAM AIDS RELIEF ANTIBIOTICS AVAILABILITY OF DRUGS BED NETS BIDDING BRAND BRAND NAME BRAND NAMES BRANDS BUDGETING CAPITAL MARKETS CASE MANAGEMENT CASH FLOW CENTRAL MEDICAL STORES CERTIFICATION CHEMISTS CIF CITIZENS CLINICAL PHARMACOLOGY CLINICAL TRIALS CLINICS COMMODITIES COMPETITIVE BIDDING CORRUPTION COUNTERFEIT DRUGS COUNTRIES OF ORIGIN DEBT FORGIVENESS DECENTRALIZATION DECISION MAKING DEVELOPING COUNTRIES DIAGNOSIS DISEASES DOMESTIC MANUFACTURERS DOMESTIC MARKET DRUG CONSUMPTION DRUG INDUSTRY DRUG PRICES DRUG SELECTION DRUG SUPPLY DRUG THERAPY DRUGS DUMPING ECONOMIC GROWTH EMERGENCY CARE ENTITLEMENT EQUAL ACCESS ESSENTIAL DRUGS ESSENTIAL MEDICINES EXPENDITURE EXPENDITURES FAMILIES FAMILY MEMBERS FRAUD GMP GOOD MANUFACTURING PRACTICES HEALTH CARE HEALTH CENTERS HEALTH FACILITIES HEALTH INSTITUTIONS HEALTH INSURANCE HEALTH OUTCOMES HEALTH PLANS HEALTH POLICY HEALTH RISKS HEALTH SECTOR HEALTH SERVICE HEALTH SERVICE PROVIDERS HEALTH SERVICES HEALTH SYSTEM HEALTH WORKERS HEALTHCARE HERBAL PRODUCTS HOSPITAL HOSPITAL PHARMACIES HOSPITALS INSURANCE COVERAGE INSURANCE SCHEMES INSURERS INTERNATIONAL MARKET INTERNATIONAL ORGANIZATIONS INVENTORY INVENTORY MANAGEMENT IRRATIONAL USE LACK OF COMMUNICATION LAND OWNERSHIP LEGAL FRAMEWORK LIFE SAVING LIMITED RESOURCES LOCAL MANUFACTURERS LOW-INCOME COUNTRIES MALARIA MANAGEMENT SYSTEMS MARKET DISTORTION MARKET RESEARCH MARKET RESEARCH FIRM MARKET SHARE MEDICAL DEVICES MEDICAL SCHOOL MEDICATION MEDICINE MEDICINES MICROBIOLOGY MIDWIVES MINISTRIES OF HEALTH MINISTRY OF HEALTH NATIONAL AIDS NATIONAL DRUG NATIONAL HEALTH POLICY PATIENT PATIENTS PAYMENT TERMS PHARMACEUTICAL PHARMACEUTICAL CONSUMPTION PHARMACEUTICAL EXPENDITURE PHARMACEUTICAL INDUSTRY PHARMACEUTICAL MANUFACTURERS PHARMACEUTICAL POLICY PHARMACEUTICAL REGULATION PHARMACEUTICAL SECTOR PHARMACEUTICAL SUPPLY PHARMACEUTICALS PHARMACISTS PHARMACY PHYSICIANS POLICY DIALOGUE POLICY FRAMEWORK POLICY GOALS POLICY IMPLICATIONS POLICY MAKERS POLITICAL SUPPORT POOLED PROCUREMENT PRESCRIPTIONS PRICE COMPETITION PRICE LEVEL PRICE LEVELS PRIVATE PHARMACIES PROCUREMENT PROGRESS PSYCHOTROPIC DRUGS PUBLIC DEBATE PUBLIC HEALTH PUBLIC PHARMACIES PUBLIC PHARMACY PURCHASING PURCHASING POWER QUALITY ASSURANCE QUALITY CONTROL RATIONAL DRUG USE RATIONAL USE OF DRUGS REGIONAL HOSPITAL REGULATORY AGENCIES RESPECT RETAIL RETAIL PHARMACIES RETAIL PRICE RETAIL PRICES ROLE MODELS RURAL AREAS SALE SALES SCREENING SELFMEDICATION SERVICE DELIVERY SERVICE DELIVERY POINTS SERVICE FACILITIES STANDARD TREATMENT GUIDELINES STOCKS SUPPLIER SUPPLIERS SUPPLY CHAIN SUPPLY CHAIN MANAGEMENT SUPPLY CHAINS SUPPLY MANAGEMENT TECHNICAL ASSISTANCE TENDERING THERAPEUTICS TOTAL SALES TREATMENT PREFERENCES TREATMENTS TURNOVER URBAN AREAS VISITS VITAMINS WAREHOUSE WHOLESALER WHOLESALERS WORKERS WORKING CONDITIONS WORLD HEALTH ORGANIZATION Main pharmaceutical policy goals in Ghana are access to essential medicines for everybody, quality assurance for all drugs on the market, a functioning and efficient supply chain as well as rational use of medicines by professionals and patients. There is also a commitment to strengthen the domestic pharmaceutical industry, outlined under health industry in the national health policy. The National Health Insurance System (NHIS) has significantly improved access to medicines for insured patients, measured in increased utilization of facilities and rapidly growing turnover of revolving drug funds. The risk is now that non-rational prescribing and fraud lead to a growing medicine bill that threatens financial sustainability of NHIS. On the other hand, National Health Insurance Authority (NHIA) has the resources and purchasing power to influence provider behavior as well as the market in terms of quality and price. The purpose of this policy note is to provide a compact overview of the situation, trends and opportunities in the pharmaceutical sector in Ghana as relevant to the strategic objectives in the five year program of work. It summarizes data from a number of recent studies and reports that were done by a range of partners inside and outside the country as well as discussions with key stakeholders in the sector. The intent is to give decision makers up-to-date background information and provide some suggestions for specific policy initiatives designed to achieve the work program objectives, with a particular focus on the role health insurance can play to stabilize and improve service delivery, increase access to quality medicines and promote rational use. The overall legal framework for the pharmaceutical sector is set by the Food and Drugs Law from 1992, amended by Act 523 in 1996. It defines the role of the food and drugs board as separate entity under control of the Ministry of Health (MOH), responsible for regulating the sector. The Food and Drugs Board (FDB) also runs the official drug quality control laboratory that is in charge of testing quality samples obtained from manufacturers, importers, distributors or other sources. The FDB is also working on an improvement of its public website in an effort to strengthen communication with the general public to increase transparency and improve governance. 2017-09-06T19:42:01Z 2017-09-06T19:42:01Z 2009-11 Policy Note http://documents.worldbank.org/curated/en/734211468030342727/The-pharmaceutical-sector-in-Ghana-policy-note http://hdl.handle.net/10986/28117 English en_US CC BY 3.0 IGO http://creativecommons.org/licenses/by/3.0/igo World Bank World Bank, Washington, DC Economic & Sector Work :: Policy Note Economic & Sector Work Africa Ghana |